



3rd Annual Biosimilars Forum

*Statistical and Regulatory Perspectives
in Bio- and Nanosimilar Development*

20
18



25–27 OCTOBER



Budapest, Hungary



**World's prominent drug development experts will return
to Budapest to the 3rd Annual Biosimilars Forum**

• *Day 1:*

PK short courses

• *Day 2:*

**Clinical studies and
regulatory questions**

• *Day 3:*

Nanosimilars

*Join us for discovery, networking and inspiration at our 3rd professional event in a row,
and focus on statistical and regulatory perspectives in bio- and nanosimilar development
with leading experts from the fields of regulatory, academic and clinical research.*



www.biosimsforum.com

3rd annual event with participation of subject matter experts and prominent professionals from the field of clinical research

This three-day series of events consists of a COURSE day with two professional masterclass sessions, a SYMPOSIUM day (invited presentations and round table discussion), and a SEMINAR DAY (lectured by special experts from the field of nanotechnology-formulated drug development), comprising issues in Bio- and Nanosimilar development.

Scientific Programme Committee



Ildikó ARADI

Head of Clinical Development of Biologics, Gedeon Richter Plc; Vice-Chair, Medicines for Europe, Biosimilar Medicines Group



Bernd JILMA

Vice Chair, Department Clinical Pharmacology, Medical University of Vienna



Franz KÖNIG

Associate Professor, Medical University of Vienna, Section for Medical Statistics



Stephan LEHR

Statistician, Austrian Medicines and Medical Devices Agency; President, Viennese Section of IBS



Julia SINGER

Chief Scientific Officer, Accelsiors; President, Hungarian Society for Clinical Biostatistics



Heike WOEHLING

Director Biostatistics for Biostatistics Biosimilars, Analytics group, Novartis

KEYNOTE PRESENTATIONS

Regulatory Keynote Presentation:

The biosimilar concept revisited – is there a need for change?



Andrea LASLOP

Unit Head, Austrian Medicines and Medical Devices Agency

Scientific Keynote Presentation:

Bioequivalence of highly variable drug products – an update



László ENDRÉNYI

Professor Emeritus of Pharmacology and Biostatistics, University of Toronto;
Co-author:
László TÓTHFALUSI

ORGANIZERS



Viennese Section of
the International
Biometric Society



Hungarian Society for
Clinical Biostatistics



Accelsiors CRO Ltd.

SPEAKERS



László ENDRÉNYI

Professor Emeritus of Pharmacology and Biostatistics, University of Toronto



Thomas JAKI

Professor of Statistics, Medical and Pharmaceutical Statistics, Lancaster University



Andrea LASLOP

Unit head, Austrian Medicines and Medical Devices Agency



Phillip PALLMANN

Deputy Director Research Design and Conduct Service, Cardiff University



Raj BAWA

President of Bawa Biotech LLC; Founding Director of American Society for



Johanna MIELKE

Early Stage Research Fellow, IDEAS Innovative Training Network



Emmanuelle VINCENT

Head of Biostatistics and Data Management, Fresenius-Kabi



János SZEBENI

Director of the Nanomedicine Research and Education Center, Semmelweis Medical University



Ludwig A. HOTHORN

Professor of Biostatistics at Leibniz Universität Hannover, Faculty of Natural Sciences,



Ágnes GYURASICS

National member of EMA Committee for Human Medicinal Products (CHMP), and EMA Paediatric Committee (PDCO); Unit Head at National Institute of Pharmacy and Nutrition



Heike WOEHLING

Director Biostatistics for Biostatistics Biosimilars, Analytics group, Novartis



Marina A. DOBROVOLSKAIA

Senior Principal Scientist and Head of the Immunology Section at the Nanotechnology Characterization Laboratory



Gert STORM

Professor of Targeted Nanomedicine at the University of Utrecht;

AGENDA



PK COURSE DAY

 **25 OCT, 2018**

with 2 professional course sessions on *statistical and pharmacokinetic aspects of biosimilarity assessment*, will be delivered by prominent biosimilar research expert scientists. Please, click [here](#) to reach the abstracts of the courses!



SYMPOSIUM DAY

 **26 OCT, 2018**

with invited professional presentations, posters and round table session, will be focusing on *statistical and regulatory perspectives in bio- and nanosimilar development*, presented by leading experts from the fields of regulatory, academic and clinical research.



SEMINAR DAY

in Nanomedicines

 **27 OCT, 2018**

NEW IN 2018: the 3rd-day consists of professional Seminar sessions regarding *current perspectives of bio- and nanosimilar drug development*, will be lectured by special international experts from the field of nanotechnology-formulated research.

PK SHORT COURSES with special lecturers

**25th OCT, 2018****8:30 - 9:00 | 1st day Registration****9:00 - 12:30 | MORNING COURSE SESSION****| Uni- and multivariate Bioequivalence of PK parameters****| *Lecturers of the Course Session: Thomas JAKI and Phillip PALLMANN*****Schedule of the course:**9:00 – 10:00 | 1st part of COURSE

10:00 – 10:20 | Coffee break: refreshments & networking

10:20 – 11:20 | 2nd part of COURSE

11:20 – 11:40 | Coffee break: refreshments & networking

11:40 – 12:30 | 3rd part of COURSE**12:30 - 14:00 | Lunch break****14:00 - 17:30 | AFTERNOON COURSE SESSION****| Statistical aspects of equivalence testing for biosimilar studies:
multiple, differently-scaled endpoints****| *Lecture of the Course Session: Ludwig A. HOTHORN*****Schedule of the course:**14:00 - 15:00 | 1st part of COURSE

15:00 - 15:20 | Coffee break: refreshments & networking

15:20 - 16:20 | 2nd part of COURSE

16:20 - 16:40 | Coffee break

16:40 - 17:30 | 3rd part of COURSE**17:30 - 18:00 | Discussion****ABSTRACTS are available at www.biosimsforum.com**

2nd DAY AGENDA

SYMPOSIUM DAY: Clinical studies and regulatory

26th OCT, 2018

9:00 - 9:30	Registration (for those attending only day 2)
9:30 - 9:50	<i>Johanna MIELKE</i> : An update on development strategies of recently approved biosimilars in Europe
9:50 - 10:30	<u>Scientific Keynote Presentation</u> <i>László ENDRÉNYI</i> (Co-author: <i>László TÓTHFALUSI</i>): Bioequivalence of highly variable drug products – an update
10:30 - 10:50	<i>Ágnes GYURASICS</i> : Challenging issues in extrapolation of totality of evidence to pediatric indications in case of biosimilars
10:50 - 11:10	Coffee break: refreshments & networking
11:10 - 11:50	<u>Regulatory Keynote Presentation</u> <i>Andrea LASLOP</i> : The biosimilar concept revisited – is there a need for change?
11:50 - 12:10	<i>Emmanuelle VINCENT</i> : Opportunities and limitations of a blinded sample size reassessment in biosimilars development
12:10 - 12:40	<i>Johanna MIELKE</i> : Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach
12:40 - 14:00	Lunch break
14:00 - 14:40	<i>János SZEBENI</i> : Animal models of immunogenicity and immune toxico-equivalence testing of nano-biopharmaceuticals <i>Presented by:</i>
14:40 - 15:10	<i>Heike WOHLING</i> : How the increase of assay sensitivity influences the immunogenicity
15:10 - 15:30	Coffee break: refreshments & networking
15:30 - 17:30	Round table discussion Moderator: <i>Helmut SCHÜTZ</i> Discussants: <ul style="list-style-type: none"> ▪ Regulatory perspective: <i>Andrea LASLOP</i> ▪ Industry perspective: <i>Heike WOHLING</i> Panel members: <ul style="list-style-type: none"> ▪ <i>Ildikó ARADI</i> ▪ <i>Ágnes GYURASICS</i> ▪ <i>Júlia SINGER</i> ▪ <i>Emmanuelle VINCENT</i> ▪ <i>Johanna MIELKE</i>

SEMINARS in Nanomeicines



27th OCT, 2018

9:00 - 9:30 | 3rd day Registration

9:30 - 12:30 | **MORNING SEMINAR SESSION**

| **The Era of Biosimilars and Nanosimilars: Current Perspectives**

| *Lecture of the Seminar: Raj BAWA*

Schedule of the course:

- 9:30 – 10:30 | 1st part of Seminar
- 10:30 – 11:00 | Coffee break: refreshments & networking
- 11:00 – 12:30 | 2nd part of Seminar

12:30 - 13:30 | **Lunch break**

13:30 - 14:15 | *Marina A. DOBROVOLSKAIA*: **The immunological characterization of nanotechnology-formulated drugs**

14:15 - 14:30 | **Coffee break: refreshments & networking**

14:30 - 15:15 | *Gert STORM*: **Targeted Nanomedicine: State of Art and Future Developments**

15:15 - 15:30 | **Coffee break: refreshments & networking**

15:30 - 16:30 | **Panel discussion**

| Moderator: *János SZEBENI*


| Panel members:

- *Raj BAWA*
- *Gert STORM*



LEARN MORE at the website of the event! www.biosimsforum.com

LOCATION OF THE EVENT



The forum is built on a modular basis, each module can be attended independently from the others. Book your place as soon as possible because places are limited in number!

REGISTRATION FEES

- 3-day event pass: € 400
- Two-day event: € 300
- 1st day courses only: € 250
- 2nd day only: € 100
- 3rd day only: € 150

WBS and ISCB members can attend the 2nd day symposium **for free**.

REGISTRATION DEADLINE

Please fill in the **Registration Form** on the webpage of the event and send us before
19th of October, 2018

CONTACT

- Contact: event@accelsiors.com

LEARN MORE ABOUT OUR PREVIOUS EVENTS

At the Annual Biosimilars Forum event series, clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on this key topic of research.

Click on the button below and take a look at the professional lectures of our events, short video interviews with the key speakers, photo galleries and more.

